Sildenafil is a candidate drug for Alzheimer’s disease: Mechanism‐of‐action observation in patient iPSC‐derived brain organoids and a 5xFAD mouse model
Evidence from real-world data, patient iPSC-derived cellular and brain organoids, and in vivo transgenic mouse model observations suggest that sildenafil is a potential repurposable treatment for AD. However, future clinical trials are necessary to test and confirm the causal relationship of sildenafil in prevention and treatment of AD.
Authors
- J Cummings
- Yichen Li (ORCID: https://orcid.org/0000-0002-9079-104X)
- Dhruv Gohel (ORCID: https://orcid.org/0000-0003-4978-6035)
- Andrew A. Pieper
- Feixiong Cheng
Institutions
- Cleveland Clinic (US)
- University of Nevada, Las Vegas (US)
- University Hospitals of Cleveland (US)
- University Hospitals Cleveland Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105583
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00